LNK in Polycystic Ovary Syndrome With Insulin Resistance

• Conditions: Polycystic Ovarian Syndrome; Insulin Resistance
• Interventions: Diagnostic Test: Take the patient's subcutaneous fat tissue to detect the expression of LNK

• Registration Number: NCT05146063
• Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Brief Summary

Insulin resistance (IR) is an important pathological feature of polycystic ovary syndrome (PCOS), with an incidence rate of up to 85%, which seriously affects the patient's fertility, quality of life, and offspring health, but the mechanism is unknown. The adaptor protein LNK is closely related to metabolic diseases. Our exome sequencing has found that the mutation rate of LNK gene in patients with PCOS and IR is high. Studies have found that LNK can affect adipose inflammation and impair glucose tolerance. Whether LNK is related to fat metabolism is worth further study. Our previous research found that: LNK expression was significantly increased in adipose tissue of patients with PCOS and IR. Knockout of LNK in PCOS IR model mice can reduce serum triglycerides, free fatty acids, high-sensitivity C-reactive protein levels and reduce fatty liver occurrence, which indicates that LNK has a mitigating effect on IR. Mechanism studies have shown that LNK knockout can upregulate the glucose transporter Glut4, also LNK and insulin receptor substrate IRS-1 can form protein complexes. Based on the above research basis, we propose the following scientific hypothesis: LNK in adipose tissue can regulate insulin signaling pathway by binding to IRS-1, downregulate Glut4, and participate in PCOS IR occurrence. This project intends to clarify the specific mechanism by which LNK regulates glucose transport and participate in IR in combination with clinical specimens, animal models and cell experiments, and provide scientific basis for LNK as a potential therapeutic target for PCOS IR.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-11
• Study Start: 2021-11-05
• Study First Submitted: 2021-11-11
• Study First Submitted QC: 2021-11-23
• Last Update Submitted: 2021-11-23
• Study First Posted: 2021-12-06
• Last Update Posted: 2021-12-06
• Primary Completion: 2022-12-31
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

• Patients with polycystic ovary syndrome who meet the 2003 Rotterdam criteria

Exclusion Criteria

• Do not meet the diagnostic criteria for polycystic ovary syndrome

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Polycystic ovary syndrome patients without insulin resistance	Take the patient's subcutaneous fat tissue to detect the expression of LNK	-
Polycystic ovary syndrome patients with insulin resistance	Take the patient's subcutaneous fat tissue to detect the expression of LNK	-

Primary Outcome Measures

Name	Time	Method
mRNA expression levels of LNK	2 years	The expression level of LNK mRNA in the subcutaneous adipose tissue of the PCOS patients
protein expression levels of LNK	2 years	The expression level of LNK protein in the subcutaneous adipose tissue of the PCOS patients

Trial Locations

Locations (1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University; 🇨🇳 Guangzhou, Guangdong, China